Hear how HTG Molecular is committed to collaborating with our investigators around the globe to address key diagnostic and therapeutic questions that can eventually be translated to empower precision medicine at the local level.
As an example, at the ASCO 2019 Clinical Science Symposium, Dr. William from M.D. Anderson and Hospital BP in Sao Paulo Brazil presented an interesting body of work around the molecular landscape of oral neoplasias and the risk of progression to malignancy.
Our next-generation sequencing (NGS)-adapted chemistry and instrument platforms automate sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets from samples a fraction of the size required by competitive technologies, enabling customers to do more molecular profiling with less sample.Learn More
HTG EdgeSeq Pan B-Cell Lymphoma panel. The newest addition to our RUO portfolio. It is designed to provide molecular characterization of aggressive lymphomas by allowing researchers to measure the expression of genes associated with the lymphoma transcriptome.
Page last updated July 27, 2020